Endo and Vernalis Provide Update on Frova
Posted on: Friday, 17 August 2007, 12:07 CDT
Endo Pharmaceuticals and Vernalis have reported that the FDA has requested more time to review their supplemental new drug application for menstrual migraine drug Frova.
The FDA indicated that it will provide a revised timeline to Endo and Vernalis, and the companies will make an announcement when appropriate. Until the companies receive further information from the FDA, they intend to continue with their existing commercial plan. The FDA has not currently requested any additional information or clinical trial data.
Frova is already approved for the treatment of migraines.
Source: Datamonitor
Related Articles
- FDA Law Enforcement: Critical to Product Safety
- FDA Considers OTC Label for 'Morning After' Pill
- FDA Removes Warning Label From Olestra
- FDA Cites Possible Suicide Link in Paxil
- FDA Recalls Lipitor Due to Fake Pills
- FDA Warns of Unapproved Impotence Remedy
- FDA to Review Treatment for Hot Flashes
- FDA OKs Anti-Nausea Pill for Chemotherapy
- FDA Proposes Standards for Supplements
- FDA Backs Anti-Nausea Drug for Some
Rating: 3.3 / 5 (6 votes)
 |
 |
Rate this article:
User Comments (0)
RSS Feeds